Artiva Biotherapeutics, Inc. (ARTV) Stock
ARTV Key Statistics
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
CEO: Fred Aslan. Company website
ARTV — Frequently Asked Questions
What is the ARTV stock price today?
Artiva Biotherapeutics, Inc. (ARTV) trades at $4.27, down 30.68% on the day, as of Nov 12, 2026 09:38 UTC.
What is Artiva Biotherapeutics, Inc.'s market cap?
Artiva Biotherapeutics, Inc. has a market capitalisation of $105.54M, calculated from the live ARTV share price and shares outstanding.
What is the P/E ratio of ARTV?
ARTV has no meaningful price-to-earnings ratio: Artiva Biotherapeutics, Inc. lost $3.43 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Artiva Biotherapeutics, Inc. make?
Artiva Biotherapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for ARTV?
ARTV has traded between $4.00 and $12.42 over the past 52 weeks, and the last price is 65.6% below that high.
Is Artiva Biotherapeutics, Inc. profitable?
Yes. Artiva Biotherapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for ARTV?
Wall Street analysts rate ARTV Buy, with an average price target of $20.50, 380.1% above the current price.
What sector is Artiva Biotherapeutics, Inc. in?
Artiva Biotherapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Artiva Biotherapeutics, Inc.?
Fred Aslan is the chief executive of Artiva Biotherapeutics, Inc., which employs 96 people.
Where can I track ARTV in real time?
QFI Terminal shows ARTV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ARTV live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ARTV in Terminal See plans